Cargando…
Emerging Modes of Treatment of IgA Nephropathy
IgA nephropathy is the most common primary glomerulonephritis with potentially serious outcome leading to end stage renal disease in 30 to 50% of patients within 20 to 30 years. Renal biopsy, which might be associated with risks of complications (bleeding and others), still remains the only reliable...
Autores principales: | Maixnerova, Dita, Tesar, Vladimir |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7730306/ https://www.ncbi.nlm.nih.gov/pubmed/33260613 http://dx.doi.org/10.3390/ijms21239064 |
Ejemplares similares
-
Expanding options of supportive care in IgA nephropathy
por: Maixnerova, Dita, et al.
Publicado: (2023) -
New Treatment Strategies for IgA Nephropathy: Targeting Plasma Cells as the Main Source of Pathogenic Antibodies
por: Maixnerova, Dita, et al.
Publicado: (2022) -
The coincidence of IgA nephropathy and Fabry disease
por: Maixnerová, Dita, et al.
Publicado: (2013) -
Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression
por: Maixnerova, Dita, et al.
Publicado: (2019) -
Correction: Galactose-deficient IgA1 and the corresponding IgG autoantibodies predict IgA nephropathy progression
por: Maixnerova, Dita, et al.
Publicado: (2019)